Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis

Zhan,Bo; Kong,Chuize; Zhang,Zhe; Dong,Xiao; Zhang,Naiwen

doi:10.3892/etm.2017.4258

Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis

Authors:
- Bo Zhan
- Chuize Kong
- Zhe Zhang
- Xiao Dong
- Naiwen Zhang
View Affiliations

Affiliations: Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/etm.2017.4258
Pages: 2473-2479

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kidney cancer is among the most important causes of cancer-associated mortality worldwide. The present study aimed to evaluate protein kinase C α (PKCα) expression in kidney cancer tissues and cell lines, and its significance in apoptosis and migration. Expression of PKCα was analyzed using quantitative polymerase chain reaction and western blotting. In addition, the inhibitor of PKCα (calphostin C and GO6976) was used to treat kidney cancer cells. The ACHN cell line was generated with PKCα-small-interfering RNA (siRNA) and a stable expression of PKCα, in order to facilitate the analysis of apoptosis and migration of PKCα during knockdown and inactivation. Flow cytometry was used to determine the rates of apoptosis. Immunohistochemical staining was used to identify the localization of PKCα in renal clear cell carcinoma and normal sections. PKCα expression in normal tissues was found to be greater than in cancerous tissues. Furthermore, apoptosis was not promoted with PKCα inhibitors or PKCα-siRNA treatment, and a decrease of the migration ability was observed following transfection with PKCα-dominant negative. The results indicated that inhibition of PKCα might not contribute to apoptosis progression in kidney carcinoma.

View Figures

View References

1	Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW and Hays RD: Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage. Cancer. 121:758–765. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr.: Rising incidence of renal cell cancer in the United States. JAMA. 281:1628–1631. 1999. View Article : Google Scholar : PubMed/NCBI
3	Webster CR, Johnston A and Anwer MS: Protein kinase Cδ protects against bile acid apoptosis by suppressing pro-apoptotic JNK and BIM pathways in human and rat hepatocytes. Am J Physiol Gastrointest Liver Physiol. 307:G1207–G1215. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:607–614. 1992. View Article : Google Scholar : PubMed/NCBI
5	Aaltonen V and Peltonen J: Protein Kinase C FamilyEncyclopedia of Cancer. Schwab M: Springer; Berlin: pp. 2469–2472. 2009
6	Fields AP and Murray NR: Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul. 48:166–178. 2008. View Article : Google Scholar : PubMed/NCBI
7	Zhang LL, Cao FF, Wang Y, Meng FL, Zhang Y, Zhong DS and Zhou QH: The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Meta-analysis of randomized controlled trials. Clin Transl Oncol. 17:371–377. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM and Brodie C: Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. 61:4612–4619. 2001.PubMed/NCBI
9	Masur K, Lang K, Niggemann B, Zanker KS and Entschladen F: High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell. 12:1973–1982. 2001. View Article : Google Scholar : PubMed/NCBI
10	Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T and Kazanietz MG: Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem. 278:33753–33762. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kong C, Zhu Y, Liu D, Yu M, Li S, Li Z, Sun Z and Liu G: Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology. 65:1228–1232. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chuize K, Yuyan Z, Zhe Z, Tao L, Meng Y and Qi Y: Protein kinase C-alpha is expressed and activated during the development of renal cell carcinoma. Urology. 76:514.e1–e5. 2010. View Article : Google Scholar
13	Zhang HT, Zhang D, Zha ZG and Hu CD: Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta. 1839:1330–1340. 2014. View Article : Google Scholar : PubMed/NCBI
14	Molè D, Gentilin E, Gagliano T, Tagliati F, Bondanelli M, Pelizzo MR, Rossi M, Filieri C, Pansini G, Uberti EC degli and Zatelli MC: Protein kinase C: A putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology. 153:2088–2098. 2012. View Article : Google Scholar : PubMed/NCBI
15	Bergelin N, Löf C, Balthasar S, Kalhori V and Törnquist K: S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 151:2994–3005. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, et al: Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 74:4822–4835. 2014. View Article : Google Scholar : PubMed/NCBI
17	Zhao Y, Zhou W, Xue L, Zhang W and Zhan Q: Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC). PLoS One. 9:e908362014. View Article : Google Scholar : PubMed/NCBI
18	Langzam L, Koren R, Gal R, Kugel V, Paz A, Farkas A and Sampson SR: Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy. Am J Clin Pathol. 116:377–385. 2001. View Article : Google Scholar : PubMed/NCBI
19	Varga A, Czifra G, Tállai B, Németh T, Kovács I, Kovács L and Bíró T: Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 46:462–465. 2004. View Article : Google Scholar : PubMed/NCBI
20	Fan J and Byron KL: Ca2+ signalling in rat vascular smooth muscle cells: A role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. J Physiol. 524:821–831. 2000. View Article : Google Scholar : PubMed/NCBI
21	Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A, Raja SM, et al: A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem. 289:30443–30458. 2014. View Article : Google Scholar : PubMed/NCBI
22	Aaltonen V, Koivunen J, Laato M and Peltonen J: PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells. Cancer Lett. 253:97–107. 2007. View Article : Google Scholar : PubMed/NCBI
23	Du HF, Ou LP, Yang X, Song XD, Fan YR, Tan B, Luo CL and Wu XH: A new PKCα/β/TBX3/E-cadherin pathway is involved in PLCε-regulated invasion and migration in human bladder cancer cells. Cell Signal. 26:580–593. 2014. View Article : Google Scholar : PubMed/NCBI
24	Qiu S, Jiang Z, Huang Z, Chen X, Qian X, Gao Q and Zheng H: Migration of retinal pigment epithelium cells is regulated by protein kinase Cα in vitro. Invest Ophthalmol Vis Sci. 54:7082–7090. 2013. View Article : Google Scholar : PubMed/NCBI